Incorporated in 2015, Pharmachal Health Group is a Melbourne-Australia-based, globally-focused unlisted public company focused on novel pharmaceutical, medical device and veterinary products.

 

Pharmachal's core focus is drug delivery, especially in the field of pain management, where it has completed two successful clinical trials with anaesthetic products harnessing its NDDS drug delivery technology.

​

The Company has signed co-development agreements with prestigious pharmaceutical institutions in Israel and internationally and is establishing a network of international distributors as it prepares to launch its first products in 2026.

​

​